Marie-Christine Vantyghem, Jérôme Cornillon, Christine Decanter, Frédérique Defrance, Wassila Karrouz, Clara Leroy, Kristell Le Mapihan, Marie-Anne Couturier, Eva De Berranger, Eric Hermet, Natacha Maillard, Ambroise Marcais, Sylvie Francois, Reza Tabrizi, Ibrahim Yakoub-Agha
Allogeneic hematopoietic stem cell transplantation is mainly indicated in bone marrow dysfunction related to blood diseases, but also in some rare diseases (adrenoleucodystrophy, mitochondrial neurogastrointestinal encephalomyopathy or MNGIE...). After decades, this treatment has proven to be efficient at the cost of numerous early and delayed side effects such as infection, graft-versus-host disease, cardiovascular complications and secondary malignancies. These complications are mainly related to the conditioning, which requires a powerful chemotherapy associated to total body irradiation (myelo-ablation) or immunosuppression (non myelo-ablation)...
October 29, 2014: Orphanet Journal of Rare Diseases